-
5m 41sPart 3 | Session 13 ACC 22: Results From the Chocolate-Touch Study
-
2m 25sPart 3 | Session 14 ACC 22: Results from the GIPS-IV Trial
-
9m 27s
-
5m 35s
-
10m 24s
-
3m 50sPart 3 | Session 18 ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study
-
4mPart 3 | Session 19 2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation
-
12m 6sPart 4 | Session 1 ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani
-
6m 15s
-
7m 9sPart 4 | Session 3 4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos
-
23m 9sPart 1 | Session 1 ACC 22 Late-breaking Science Preview
-
28m 6sPart 1 | Session 2 ACC.22 Late-breaking Science Wrap-Up
-
16m 42sPart 2 | Session 1 ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial
-
16m 57sPart 2 | Session 2 ACC 2022 Late-breaker Discussion: The SuperWIN Trial
-
15m 38sPart 2 | Session 3 ACC 22 Late-breaker Discussion: The PROMPT-HF Trial
-
22m 47sPart 2 | Session 4 ACC 22 Late-breaker Discussion: The DIAMOND Trial
-
9m 38sPart 3 | Session 1 ACC 22: Findings from the VALOR-HCM Trial
-
7m 19s
-
3m 19sPart 3 | Session 3 ACC 22: Results From the PACIFIC AF Trial
-
3m 6s
-
3m 54sPart 3 | Session 5 ACC 22: Results from the TRANSLATE-TIMI 70 Trial
-
4m 22sPart 3 | Session 6 ACC 22: Results from the POISE-3 Trial
-
6m 30sPart 3 | Session 7 ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia
-
6m 3s
-
3m 31sPart 3 | Session 9 ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)
-
4m 48sPart 3 | Session 10 ACC 22: Results From a sub-study of the POISE-3 Trial
-
2m 55sPart 3 | Session 11 ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Faculty Biographies
Duk-Woo Park
Professor of Medicine
Prof Duk-Woo Park is Professor in the Cardiovascular Medicine Division at Asan Medical Center, Seoul, Korea, and an Instructor in Medicine at the University of Ulsan College of Medicine.
Prof Park has a particular interest in revascularization strategy (PCI vs. CABG for multivessel and left main disease), antiplatelet/antithrombotic strategey, transcatheter valve interventions (TAVR), major clinical trials or registries studies (drugs, stents, revascularization strategy), biomarkers, and medical statistics.